RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

About this update from Rxsight, Inc.

[{"type":"image","alt":"RxSight, Inc.","displaySize":"","headline":null,"caption":"RxSight, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RlZbsYuiF8.V1Nc6BC4.Lw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4","width":300,"height":92}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time.","length":433,"tagName":"p"},{"type":"text","content":"Preliminary First Quarter 2025 Results","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, representing growth of 28% compared to the prior year period, and a decrease of 6% compared to the fourth quarter of 2024, driven by:","length":219,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+®); representing a 36% increase in procedure volume compared to the first quarter of 2024; and","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of March 31, 2025, which represents a 43% expansion compared to the installed base of 732 LDDs at end of the first quarter of 2024.","length":223,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":370,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":589,"olType":false},{"type":"text","content":"“Given RxSight’s more significant installed base of surgeons and practices, we now must navigate headwinds affecting the overall premium IOL market and broader economy that were less impactful when our commercial footprint was much smaller,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSi...

More updates from Rxsight, Inc.